A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Moderate to Severe Psoriasis

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Moderate to Severe Psoriasis

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2013

At a glance

  • Drugs AMG 811 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jul 2012 Planned end date changed from 1 Aug 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 13 Jul 2012 Additional location (USA) added as reported by ClinicalTrials.gov.
    • 25 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top